CTKB — Cytek Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $476.24m
- $215.54m
- $200.45m
- 82
- 45
- 19
- 47
Annual cashflow statement for Cytek Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 19.4 | 3.03 | 2.48 | -12.1 | -6.02 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.68 | 8.72 | 19.6 | 18.4 | 16.1 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.54 | -8.36 | -39.9 | -10.2 | 7.71 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 15.2 | 4.63 | -12.2 | 5.28 | 25.4 |
| Capital Expenditures | -1.55 | -4.36 | -9.87 | -4.83 | -3.73 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -16.6 | -46 | -89.1 | -79.2 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.55 | -21 | -55.9 | -93.9 | -83 |
| Financing Cash Flow Items | — | — | -0.209 | -0.419 | -0.554 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 123 | 214 | 5.51 | -41.8 | -15.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 136 | 198 | -65.1 | -132 | -68.9 |